Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rMenB+OMV NZ Extension Study in 4-Year-Olds
NCT01717638Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Sep 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease, sponsored by Novartis. Started Nov 2012; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01717638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01717638.